For now, there’s no hard and fast rule when it comes to the slippery slope CBD companies will have to contend with until the FDA starts approving products. Until then, it’s best to err on the side of caution and avoid making any claims you can’t back up with hard science and cited studies, lest draw the ire of government officials who can and will put you out of business if you don’t heed their warnings.
Twenty patient associations from across northeastern Brazil are meeting in Fortaleza this month, inside a…
In 1968, a few joints I gave away left me facing the possibility of decades…
Here's the part that should worry every operator, investor, and vendor in the industry: this…
For one hash maker the clock starts at harvest, and the flower is in the…
Cannabis can absolutely take you somewhere that looks like a classic psychedelic experience. It just…
Researchers analyzing two ancient skeletons from Indonesia found dramatic dental wear and traces of arecoline,…